nach oben

Drugs

Erschienen in:

01.12.2001 | Adis New Formulation Profile

Once-Weekly Fluoxetine

A Viewpoint by Alexander Neumeister and W. Wolfgang Fleischhacker

verfasst von: Alexander Neumeister, W. Wolfgang Fleischhacker

Erschienen in: Drugs | Ausgabe 15/2001

Einloggen, um Zugang zu erhalten

Excerpt

Epidemiological studies and long-term treatment trials have demonstrated that major depressive disorder (MDD) is a recurrent, chronic disorder with increasing psychosocial impairment and an increased risk for suicidality if the disorder is not adequately treated.[1] Quality-improvement programmes using evidence-based treatments for MDD have been shown to improve standards of care and clinical outcomes for MDD with both short-term[2,3] and long-term[4] follow-up. …

Keller MB. Long-term treatment of recurrent and chronic depression. J Clin Psychiatry 2001; 62 Suppl. 24: 3–5PubMed

Katon W, Von Korff M, Lin E, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry 1999; 56(12): 1109–15PubMedCrossRef

Katon W, Robinson P, Von Korff M, et al. A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry 1996; 53(10): 924–32PubMedCrossRef

Unutzer J, Rubenstein L, Katon WJ, et al. Two-year effects of quality improvement programs on medication management for depression. Arch Gen Psychiatry 2001; 58(10): 935–42PubMedCrossRef

Schmidt ME, Fava M, Robinson JM, et al. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry 2000 Nov; 61(11): 851–7PubMedCrossRef

Miner CM, Brown EB, Gonzales JS, et al. Switching patients from daily citalopram, paroxetine or sertraline to fluoxetine once-weekly in the maintenance of response for depression. 2001 Indianapolis (IN): Eli Lilly and Company. (Data on file)

Claxton A, de Klerk E, Parry M, et al. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry 2000 Dec; 61(12): 928–32PubMedCrossRef

Oehl M, Hummer M, Fleischhacker WW. Compliance with anti-psychotic treatment. Acta Psychiatr Scand Suppl 2000; 102(407): 83–6CrossRef

Reimherr FW, Strong RE, Marchant BK, et al. Factors affecting return of symptoms 1 year after treatment in a 62-week controlled study of fluoxetine in major depression. J Clin Psychiatry 2001; 62 Suppl. 22: 16–23PubMed

Titel: Once-Weekly Fluoxetine
A Viewpoint by Alexander Neumeister and W. Wolfgang Fleischhacker
verfasst von: Alexander Neumeister
W. Wolfgang Fleischhacker
Publikationsdatum: 01.12.2001
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 15/2001
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200161150-00008

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Once-Weekly Fluoxetine

A Viewpoint by Alexander Neumeister and W. Wolfgang Fleischhacker

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15/2001

Cetirizine/Pseudoephedrine

Pharmacological Options for the Treatment of Tourette’s Disorder

Renal Toxicity with Sevoflurane

Cetirizine/Pseudoephedrine

Estradiol-Intranasal

Cetirizine/Pseudoephedrine